From Wikipedia, the free encyclopedia
(Redirected from BCX-1777)
|Jmol-3D images||Image 1|
|Molar mass||266.25 g/mol|
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)|
|(what is: / ?)|
Forodesine (INN; also known as Immucillin H) is a transition-state analog inhibitor of purine nucleoside phosphorylase under development for the treatment of relapsed B-cell chronic lymphocytic leukemia
- Kicska GA, Long L, Hörig H, et al. (April 2001). "Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes". Proc. Natl. Acad. Sci. U.S.A. 98 (8): 4593–8. doi:10.1073/pnas.071050798. PMC 31879. PMID 11287638.
- "Complete list of clinical trials for forodesine (BCX-1777) (ClinicalTrials.gov)". Retrieved 2008-07-22.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|